Product logins

Find logins to all Clarivate products below.


Key trends to watch

The trends shaping drug development and patient health outcomes in 2025 and beyond 

Regulators are prioritizing equitable health access and patient preferences, underscoring the need for innovators to demonstrate the value of their products using emerging tools such as patient-reported outcomes and AI/machine learning. 2024 saw a number of regulatory firsts, including novel treatments for Niemann-Pick disease type C and GNE myopathy, as well as the first tumor infiltrating lymphocite treatment to win approval. Meanwhile, GLP-1s are revolutionizing treatment of obesity and diabetes while the emergence of radiopharmaceuticals promises leaps in the treatment and diagnosis of a plethora of diseases.

These trends demonstrate the industry’s continuing innovation as well as regulatory agencies’ commitment to filling treatment gaps for patient populations with high unmet needs.

Read more in our Blog section.

Key trends

Drug combinations: your questions answered Drug combinations: your questions answered
Blog November 19, 2024
Drug combinations: your questions answered

Developing drug combinations is a complex process with challenges and opportunities that can significantly impact patient outcomes. Diseases such as cancer often involve multiple molecular pathways, so single drugs may…

These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers

It has been a long, slow road to the recent frenzy in antibody drug conjugate (ADC) activity. After the first publication of an experimental ADC design 60 years ago, it…

What a string of semaglutide biosimilars could mean for Mainland China What a string of semaglutide biosimilars could mean for Mainland China
Blog May 14, 2024
What a string of semaglutide biosimilars could mean for Mainland China

The Mainland China market for GLP-1 drugs to treat obesity and diabetes is valued at approximately $1.7 billion.

Real world data reveal how diseases manifest in diverse populations Real world data reveal how diseases manifest in diverse populations
Blog April 4, 2024
Real world data reveal how diseases manifest in diverse populations

The prevalence and co-occurrence of immune-mediated inflammatory diseases (IMIDs) like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity among U.S. adults. That’s the upshot of a retrospective…

chevron_left
chevron_right